Cargando…

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study

OBJECTIVE: Fenfluramine, which was previously approved as a weight loss drug, was withdrawn in 1997 when reports of cardiac valvulopathy emerged. The present study was conducted in part to characterize the cardiovascular safety profile of low‐dose fenfluramine when used in a pediatric population to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Wyman W., Galer, Bradley S., Wong, Pierre C., Farfel, Gail, Pringsheim, Milka, Keane, Martin G., Agarwal, Anupam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754414/ https://www.ncbi.nlm.nih.gov/pubmed/32809271 http://dx.doi.org/10.1111/epi.16638

Ejemplares similares

Fenfluramine HCl (Fintepla(®)) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study
por: Sullivan, Joseph, et al.
Publicado: (2020)

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial
por: Nabbout, Rima, et al.
Publicado: (2020)

An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program
por: Guerrini, Renzo, et al.
Publicado: (2022)

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study
por: Knupp, Kelly G., et al.
Publicado: (2022)

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial
por: Devinsky, Orrin, et al.
Publicado: (2018)

Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial
por: Knupp, Kelly G., et al.
Publicado: (2022)

Fenfluramine: New Treatment for Seizures in Dravet Syndrome
por: Pierce, Joanna Garcia, et al.
Publicado: (2020)

A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
por: Boyd, Brooks, et al.
Publicado: (2019)

A review of fenfluramine for the treatment of Dravet syndrome patients
por: Simon, Kayla, et al.
Publicado: (2021)

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
por: Frampton, James E.
Publicado: (2023)

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
por: Frampton, James E.
Publicado: (2023)

Low‐dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients
por: Schoonjans, A., et al.
Publicado: (2016)

Fenfluramine in the successful treatment of super-refractory status epilepticus in a patient with Dravet syndrome
por: Millett, David, et al.
Publicado: (2021)

Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis
por: Sullivan, Joseph, et al.
Publicado: (2021)

Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
por: Li, Jing, et al.
Publicado: (2021)

Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
por: Trinka, Eugen, et al.
Publicado: (2020)

Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study
por: French, Jacqueline A., et al.
Publicado: (2021)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine
por: Zhang, Yifan, et al.
Publicado: (2015)

Assessment of the long‐term efficacy and safety of adjunctive perampanel in tonic‐clonic seizures: Analysis of four open‐label extension studies
por: Rektor, Ivan, et al.
Publicado: (2020)

Fenfluramine: A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy
por: Samanta, Debopam
Publicado: (2022)

Defining Dravet syndrome: An essential pre‐requisite for precision medicine trials
por: Li, Wenhui, et al.
Publicado: (2021)

Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis
por: Tabaee Damavandi, Payam, et al.
Publicado: (2023)

A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
por: Heger, Katrine, et al.
Publicado: (2020)

Autism spectrum disorder and cognitive profile in children with Dravet syndrome: Delineation of a specific phenotype
por: Ouss, Lisa, et al.
Publicado: (2018)

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India
por: Mehndiratta, Man M., et al.
Publicado: (2021)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program
por: Pernici, Chelsea D., et al.
Publicado: (2021)

High FGF‐21 level in a cohort of 22 patients with Dravet Syndrome—Possible relationship with the disease outcomes
por: Kwong, Anna Ka‐Yee, et al.
Publicado: (2021)

Soticlestat, a novel cholesterol 24‐hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
por: Hawkins, Nicole A., et al.
Publicado: (2021)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
por: Burmester, Gerd R, et al.
Publicado: (2019)

Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study
por: Sperling, Michael R., et al.
Publicado: (2020)

Consistent safety and tolerability of Valtoco(®) (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long‐term, open‐label, repeat‐dose safety study
por: Miller, Ian, et al.
Publicado: (2021)

Fenfluramine: a plethora of mechanisms?
por: Sourbron, Jo, et al.
Publicado: (2023)

Initial and ongoing tobacco smoking elicits vascular damage and distinct inflammatory response linked to neurodegeneration
por: Garza, Alejandra P., et al.
Publicado: (2023)

Retinal safety and toxicity study of artesunate in vitro and in vivo
por: Lu, Bing-Wen, et al.
Publicado: (2022)

Update meta-analysis on the efficacy and safety issues of fexofenadine
por: Gómez, René Maximiliano, et al.
Publicado: (2023)

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
por: Fogarasi, Andras, et al.
Publicado: (2020)

Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
por: Wheless, James W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ms4fhpjr1n9s9c6ivomdrqof8